ロード中...
Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals
The recently developed anti‐androgen enzalutamide also known as (MDV3100) has the advantage to prolong by 4.8 months the survival of castration resistant prostate cancer (CRPC) patients. However, the mechanisms behind the potential side effects involving the induction of the prostate cancer (PCa) ne...
保存先:
| 出版年: | Mol Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528811/ https://ncbi.nlm.nih.gov/pubmed/25817444 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.02.010 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|